Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - cobicistat 150mg (as a blend with silicon dioxide);  ;  ;  ; elvitegravir 150mg;  ;  ; emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide 10mg (as tenofovir alafenamide fumarate 11.2mg);   - tablet - active: cobicistat 150mg (as a blend with silicon dioxide)       elvitegravir 150mg     emtricitabine 200mg         tenofovir alafenamide 10mg (as tenofovir alafenamide fumarate 11.2mg)   excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 85f110095 sodium laurilsulfate - genvoya is indicated as a single tablet regimen for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are either treatment-na?ve; or virologically suppressed (hiv-1 rna genvoya is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - amphotericin b 50mg - powder for injection - 50 mg - active: amphotericin b 50mg excipient: cholesterol hydrochloric acid alpha-tocopherol distearoylphosphatidylglycerol phosphatidylcholines, soya, hydrogenated phosphatidylglycerols as sodium salt sodium hydroxide sodium succinate sucrose - ambisome is indicated for: · prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for · the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b. ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - cobicistat 150mg;  ;  ;  ; elvitegravir 150mg;  ;  ; emtricitabine 200mg;  ;  ;  ;  ; tenofovir disoproxil fumarate 300mg;  ;  ;   - film coated tablet - active: cobicistat 150mg       elvitegravir 150mg     emtricitabine 200mg         tenofovir disoproxil fumarate 300mg       excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry green sodium laurilsulfate - stribild is indicated as a single tablet regimen for the treatment of hiv infection in treatment-naive adults. stribild is also indicated in certain virologically suppressed (hiv1 rna stribild is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - cobicistat 150mg;  ;  ;   - film coated tablet - 150 mg - active: cobicistat 150mg       excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry orange 85f93642 - tybost is indicated as a pharmacokinetic enhancer of appropriate hiv-1 protease inhibitors in adults

Australia - inglese - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: hydrogenated soy phosphatidylcholine; sucrose; dl-alpha-tocopherol; distearoylphosphatidylglycerol; sodium succinate; cholesterol - indications: ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum. indicated as at 8 september 2003 :ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Israele - inglese - Ministry of Health

gilead sciences israel ltd - lenacapavir as sodium - solution for injection - lenacapavir as sodium 309 mg/ml - lenacapavir - sunlenca solution for injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Israele - inglese - Ministry of Health

gilead sciences israel ltd - tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - tenofovir disoproxil - viread is indicated for the treatment of :1. hiv 1 infected adults and pediatric patients 12 years of age and older in combination with other antiretroviral medicinal products for the treatment of hiv. 2. chronic hepatitis b in adults with: • compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. • decompensated liver disease

Israele - inglese - Ministry of Health

gilead sciences israel ltd - tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - tenofovir disoproxil - viread is indicated for the treatment of :1. hiv 1 infected adults and pediatric patients 12 years of age and older in combination with other antiretroviral medicinal products for the treatment of hiv. 2. chronic hepatitis b in adults with: • compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. • decompensated liver disease

Israele - inglese - Ministry of Health

gilead sciences israel ltd - tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - viread is indicated for the treatment of :1. hiv 1 infected adults and pediatric patients 12 years of age and older in combination with other antiretroviral medicinal products for the treatment of hiv. 2. chronic hepatitis b in adults with: • compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. • decompensated liver disease

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - ledipasvir 90mg;  ;  ; sofosbuvir 400mg;  ;  ;   - film coated tablet - 90mg/400mg - active: ledipasvir 90mg     sofosbuvir 400mg       excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 85f13912 - harvoni is indicated for the treatment of chronic hepatitis c (chc) infection in adults and in pediatric patients 12 years of age and older or weighing at least 35 kg with genotype 1, 4, 5 or 6 without cirrhosis or with compensated cirrhosis.